|
ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of …
The Herald | HeraldOnline.com “We are encouraged by the evidence of antitumor activity of IGN002 observed in pre-clinical studies in rituximab-resistant tumor models and are preparing for an IND filing for IGN002 in the second half of 2014.” About IGN002. IGN002, a fusion molecule … |
Infinity Reports Updated Phase 1 Data Showing Encouraging Clinical Activity of …Wall Street JournalAn investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination wi…
WUSTL engineer to develop new biosensors with NSF Career AwardEurekAlert (press release)With the five-year, $400,000 award, Singamaneni plans to create a novel class of biosensors based on self-assembled clusters of metal nanoparticles that have been i…
Study Hints of Rituximab MS BenefitMedPage TodayAmong 25 patients with secondary progressive MS treated with rituximab, nine showed decreases in disability and 12 appeared to stabilize after receiving at least two cycles of rituximab given every 3 mont…
CHICAGO, Jun 03, 2013 (BUSINESS WIRE) — — Rapid Onset of Clinical Activity …MarketWatch (press release)An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combina…
|
TG Therapeutics, Inc. Announces Presentation of Interim Results From Its Phase …
NASDAQ (press release) NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. ( TGTX ) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s … |
|
TG Therapeutics , Inc . Announces Presentation of Interim Results From Its …
MarketWatch TG Therapeutics, Inc. (TGTX) today announced preliminary results from a Phase 1 clinical study of single-agent ublituximab (TG-1101) in patients with rituximab relapsed and/or refractory Non-Hodgkin’s Lymphoma (NHL), presented at the American Society … |
Scientists develop new method for finding therapeutic antibodiesdomain-BScientists at The Scripps Research Institute (TSRI) at La Jolla, California, have devised a powerful new technique for finding antibodies that have a desired biological effect. Ant…
Symphogen Reports New Data on Anti-EGFR Monoclonal Antibody MixturePipelineReview.com (press release)COPENHAGEN, Denmark I June 2, 2013 I Symphogen, a private biopharmaceutical company developing recombinant antibody mixtures, announced today at the 20…
|
Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s?
PsychCentral.com (blog) Could Antibodies or Hormones Slow Brain Damage from Alzheimer’s? Scientists have discovered that certain antibodies may help slow the progression of Alzheimer’s disease. Dr. Patricia Salinas of University College London, UK, and her team focused on a … |